CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
MAC26 (S1706) trial has been centrally activated, this is a Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
CCTG Spring meeting travel expenses are reimbursed only by submitting a properly completed travel expense claim form. This form, accompanied by original documents, should be submitted to CCTG Group Administrator’s Office no later than 30 June 2019.
Dr. Khalil Sultanem is a Radiation Oncologist working at the Jewish General Hospital at McGill University. He is involved in the Head and Neck disease site committee at CCTG and is the Co-Chair of the HN9 study. Dr. Sultanem believes the HN9 study is a unique and innovative study because it provides a possibility to replace chemotherapy, which is toxic, with immunotherapy.
The Canadian Cancer Trials Group (CCTG) has been awarded more than 19 million USD over six years (approximately $25 million CAD) from the U.S. National Institutes of Health (NIH) and National Cancer Institute (NCI). This award will allow the group to continue their work leading major cancer clinical trials in Canada through the US National Clinical Trials Network (NCTN) and to develop new large scale trials under CCTG leadership.
A primary publication for the CCTG IND219 - A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-Based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer
CCTG HNC2 (NRG HN004) - Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin Has now been centrally activated in Canada, the trial is being led by NRG Oncology in the US, and CCTG is sponsor in Canada.
Did you know that we have some amazing music talent hiding in ranks of CCTG? There has been a friendly (?) music rivalry between Dr. Jim Biagi (Old DOCS New Tricks) and Dr. Dan Renouf (Desolation Sound Machine) and they are letting everyone at the CCTG Spring Meeting be entertained and be the judges of who has the best band.
Every year at the CCTG Spring Meeting we recognize individuals who have contributed significantly to the mission and activities of the Canadian Cancer Trials Group. Presentation of the awards will happen at the Recognition Awards Ceremony on Friday May 3 from 5:30 to 6:00 at the Chelsea Hotel in Toronto. We are honored to acknowledge the 2019 CCTG Recognition Awards winners.
